Letter to the Editor From Taguchi: "Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS"

Affiliations

Comment

Akira Taguchi. J Clin Endocrinol Metab. 2022.

. 2022 May 17;107(6):e2646.

doi: 10.1210/clinem/dgac109.

¹ Department of Oral and Maxillofacial Radiology, School of Dentistry, Matsumoto Dental University, Hirooka, Shiojiri, Nagano, 399-0781, Japan.

No abstract available

Comment in

Response to Letter to the Editor From Taguchi: "Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS".
Anastasilakis AD, Pepe J, Napoli N, Palermo A, Magopoulos C, Khan AA, Zillikens MC, Body JJ. Anastasilakis AD, et al. J Clin Endocrinol Metab. 2022 May 17;107(6):e2651-e2652. doi: 10.1210/clinem/dgac111. J Clin Endocrinol Metab. 2022. PMID: 35213729 Free PMC article. No abstract available.

Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.
Anastasilakis AD, Pepe J, Napoli N, Palermo A, Magopoulos C, Khan AA, Zillikens MC, Body JJ. Anastasilakis AD, et al. J Clin Endocrinol Metab. 2022 Apr 19;107(5):1441-1460. doi: 10.1210/clinem/dgab888. J Clin Endocrinol Metab. 2022. PMID: 34922381 Free PMC article. Review.